Cancerous disease modifying antibodies
OwnerDavid S. F. Young, Helen P. Findlay +1inventors
InventorsDavid S. F. Young, Helen P. Findlay, Susan E. Hahn
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
Claims36
A method of extending survival and delaying disease progression by treating a human tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to a monoclonal antibody or antigen binding fragment thereof which has the identifying characteristics of a monoclonal antibody encoded by a clone deposited with the ATCC as accession number PTA-4890 comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden, whereby disease progression is delayed and survival is extended.
An isolated monoclonal antibody or antigen binding fragments thereof encoded by the clone deposited with the ATCC as PTA-4890.
The isolated clone deposited with the ATCC as PTA-4890.
A binding assay to determine presence of cancerous cells in a tissue sample selected from a human tumor comprising:
- providing a tissue sample from said human tumor;
- providing an isolated monoclonal antibody or antigen binding fragment thereof encoded by the clone deposited with the ATCC as PTA-4890;
- contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- and
- determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- whereby the presence of said cancerous cells in said tissue sample is indicated.
A process of isolating or screening for cancerous cells in a tissue sample selected from a human tumor comprising:
- providing a tissue sample from a said human tumor;
- providing an isolated monoclonal antibody or antigen binding fragment thereof encoded by the clone deposited with the ATCC as PTA-4890;
- contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- and
- determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- whereby said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.
A method of extending survival and delaying disease progression by treating a human tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to a monoclonal antibody or antigen binding fragment thereof which has the identifying characteristics of a monoclonal antibody encoded by a clone deposited with the ATCC as accession number PTA-4889 comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden, whereby disease progression is delayed and survival is extended.
An isolated monoclonal antibody or antigen binding fragments thereof encoded by the clone deposited with the ATCC as PTA-4889.
The isolated clone deposited with the ATCC as PTA-4889.
A binding assay to determine presence of cancerous cells in a tissue sample selected from a human tumor comprising:
- providing a tissue sample from said human tumor;
- providing an isolated monoclonal antibody or antigen binding fragment thereof encoded by the clone deposited with the ATCC as PTA-4889;
- contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- and
- determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- whereby the presence of said cancerous cells in said tissue sample is indicated.
A process of isolating or screening for cancerous cells in a tissue sample selected from a human tumor comprising:
- providing a tissue sample from a said human tumor;
- providing an isolated monoclonal antibody or antigen binding fragment thereof encoded by the clone deposited with the ATCC as PTA-4889;
- contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- and
- determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
- whereby said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.
Dependencies are inferred from the claim text.